Manufacturer
Merck Sharp & Dohme
Contents
Sitagliptin 50 mg, metformin HCl extended-release 500 mg
Indication
As initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. As adjunct to diet & exercise to improve glycemic control in type 2 DM inadequately controlled on metformin or sitagliptin alone, or combination sitagliptin & metformin, or triple combination sitagliptin, metformin or a sulfonylurea, or max tolerated dose of metformin & a PPARγ agonist, or insulin & metformin alone.
Instruction
Should be taken with food: Take preferably in the evening. Do not split/break/crush/chew tab.
Drug interaction
Metformin: Furosemide, nifedipine, cationic drugs (eg, amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin). Thiazides & other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, OCs, phenytoin, nicotinic acid, sympathomimetics, Ca antagonists, INH.
Drug interaction
Malaysia
